Brief: Black Diamond Therapeutics Announces Corporate Update And Expected 2024 Milestones

Black Diamond Therapeutics

04/01/2024 13:57

Jan 4 (Reuters) - Black Diamond Therapeutics Inc
 BDTX.O :
    * BLACK DIAMOND THERAPEUTICS ANNOUNCES CORPORATE UPDATE AND
EXPECTED 2024 MILESTONES
    * FDA FEEDBACK ON BDTX-1535 ENABLES INITIATION OF PHASE 2
COHORT
IN FIRST-LINE TREATMENT OF NON-CLASSICAL EGFR MUTANT NSCLC
    * FAST TRACK DESIGNATION GRANTED FOR BDTX-1535 AS
SECOND-LINE
TREATMENT FOR EGFR MUTANT/C797S NSCLC
    * BDTX-1535 PHASE 2 RESULTS FOR 2L/3L PATIENTS WITH EGFR
MUTANT
NSCLC EXPECTED Q3 2024
    * BDTX-4933 PHASE 1 RESULTS IN PATIENTS WITH KRAS MUTANT
NSCLC
EXPECTED Q4 2024
    * EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE
SUFFICIENT
TO FUND MILESTONE ACHIEVEMENTS & OPERATIONS INTO Q2 2025

Source text for Eikon:  ID:nGNX2j10Rz 
Further company coverage:  BDTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))